Alexandra Indeglia

This study identifies BRD2 as a co-targetable vulnerability with PI3K/AKT inhibitors in breast cancer, showing that BRD2 phosphorylation is required for chromatin binding and that targeting BRD2 enhances drug efficacy.

This paper develops a digital twin model to optimize epigenetic therapies in triple-negative breast cancer by simulating treatment responses and identifying effective drug combinations.

This study shows that p53 variants with R181 mutations retain mitochondrial apoptosis function but lose DNA binding cooperativity, leading to reduced cancer risk.

This study identifies NAB2-STAT6 as a driver of a neuroendocrine program in SFTs through its role in enhancing EGR1 target gene expression.

This study shows that RAS signaling regulates Timp2 alternative polyadenylation isoforms, with the long 3UTR isoform enhancing secreted protein expression and contributing to cell transformation.